FDA extends review period for Ascendis Pharma's first drug

Ascendis Pharma has to wait three more months for the FDA to give its verdict on the firm's drug lonapegsomatropin for treating pediatric growth hormone deficiency.
Photo: Kevin Grønnemann
Photo: Kevin Grønnemann
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Just two weeks before the deadline, the US Food and Drug Administration (FDA) has extended the review period for Ascendis Pharma's first drug candidate lonapegsomatropin, according to an Ascendis Pharma press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading